Back to main

Pfizer Files 8K - Regulation FD

Pfizer Inc. (PFE) filed a Form 8K - Regulation FD Disclosure - with the U.S Securities and Exchange Commission on May 27, 2014.

On May 26, 2014, Pfizer Inc. issued an announcement (the "Announcement") pursuant to Rule 2.8 of the U.K. City Code on Takeovers and Mergers announcing that it does not intend to make an offer for AstraZeneca plc. A copy of the Announcement is attached hereto as Exhibit 99.1 and is incorporated by reference into this Item 7.01.

Pursuant to General Instruction B.2. to Form 8-K, the information set forth in this Item 7.01 (except insofar as such information is also set forth under Item 8.01 below) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section.

The full text of this SEC filing can be retrieved at: d732803d8k.htm

Any exhibits and associated documents for this SEC filing can be retrieved at: 78003/000119312514212123/0001193125-14-212123-index.htm

Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.

Access Investor Kit for Pfizer Inc.


Subscribe to WSJ:

  (END) Dow Jones Newswires
  Copyright (c) 2014 Dow Jones & Company, Inc.